Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1359-1369

  Obach, R Scott ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; PROPRANOLOL DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG CLEARANCE; ENZYME KINETICS; ENZYME SPECIFICITY; INSECT; LIVER CLEARANCE; MICROSOME; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; SPECIES DIFFERENTIATION;

ANIMALS; BLOOD PROTEINS; CELL LINE; DOGS; ENZYME ACTIVATION; HAPLORHINI; HUMANS; IMIPRAMINE; METABOLIC CLEARANCE RATE; MICROSOMES; MICROSOMES, LIVER; PROPRANOLOL; PROTEIN BINDING; RATS; SPODOPTERA; WARFARIN;

EID: 0031466149     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. G. R. Wilkinson and D. G. Shand: A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18, 377-390 (1975).
2. K. S. Pang and M. Rowland: Hepatic clearance of drugs: I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model: influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5, 625-653 (1977).
3. A. Rane, G. R. Wilkinson, and D. G. Shand: Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200, 420-424 (1977).
4. J. B. Houston: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469-1479 (1994).
5. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, and Y. Sugiyama: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73, 147-171 (1997).
6. P. Skett, C. Tyson, A. Guillouzo, and P. Maier: Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Biochem. Pharmacol. 50, 280-285 (1995).
7. R. S. Obach: The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab. Dispos. 24, 1047-1049 (1996).
8. C. Baarnhielm, H. Dahlback, and I. Skanberg: In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog, and man. Acta Pharmacol. Toxicol. 59, 113-122 (1986).
9. D. M. Kornhauser, A. J. J. Wood, R. E. Vestal, G. R. Wilkinson, R. A. Branch, and D. G. Shand: Biological determinants of propranolol disposition in man. Clin. Pharmacol. Ther. 23, 165-174 (1978).
10. P. A. O'Reilly: Sodium warfarin. Pharmacology 8, 181-190 (1972).
11. A. H. Glassman, M. J. Hurwic, and J. M. Perel: Plasma binding of imipramine and clinical outcome. Am. J. Psychiat. 130, 1367-1369 (1973).
12. C. B. Kristensen: Imipramine serum protein binding in healthy subjects. Clin. Pharmacol. Ther. 34, 689-694 (1983).
13. F. R. Sallee and B. G. Pollack: Clinical pharmacokinetics of imipramine and desipramine. Clin. Pharmacokinet. 18, 346-364 (1990).
14. J. H. Lin, M. Hayashi, S. Awazu, and M. Hanano: Correlation between in vitro and in vivo drug metabolism rate: oxidation of ethoxybenzamide in rat. J. Pharmacokinet. Biopharm. 6, 327-337 (1978).
15. J. H. Lin, Y. Sugiyama, S. Awazu, and M. Hanano: Kinetic studies on the deethylation of ethoxybenzamide: a comparative study with isolated hepatocytes and liver microsomes of rat. Biochem. Pharmacol. 29, 2825-2830 (1980).
16. M. Chiba, S. Fujita, and T. Suzuki: Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. J. Pharm. Sci. 79, 281-287 (1990).
17. M. V. St. Pierre and K. S. Pang: Concentration dependent metabolism of diazepam in the mouse. J. Pharmacokinet. Biopharm. 23, 243-266 (1995).
18. M values: implications for clinical correlation. J. Pharmacol. Exp. Ther. 282, 391-396 (1997).
19. M. H. Bickel and J. W. Steele: Binding of basic and acidic drugs to rat tissue subcellular fractions. Chem.-Biol. Interact. 8, 151-162 (1974).
20. C. DiFrancesco and M. H. Bickel: Membrane lipids as intracellular binders of chlorpromazine and related drugs. Chem.-Biol. Interact. 16, 335-346 (1977).
21. P. H. Marathe, D. D. Shen, and W. L. Nelson: Metabolic kinetics of pseudoracemic propranolol in human liver microsomes: enantioselectivity and quinidine inhibition. Drug Metab. Dispos. 22, 237-247 (1994).
22. S. V. Otton, E. M. J. Gillam, M. S. Lennard, G. T. Tucker, and H. F. Woods: Propranolol oxidation by human liver microsomes-the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity. Br. J. Clin. Pharmacol. 30, 751-760 (1990).
23. A. E. Rettie, A. C. Eddy, L. D. Heimark, M. Gibaldi, and W. F. Trager: Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17, 265-270 (1989).
24. R. J. Lewis, W. F. Trager, K. K. Chan, A. Breckenridge, M. Orme, M. Rowland, and W. Schary: Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J. Clin. Invest. 53, 1607-1617.
25. A. Lemoine, J. C. Gautier, D. Azoulay, L. Kiffel, C. Belloc, F. P. Guengerich, P. Maurel, P. Beaune, and J. P. Leroux: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43, 827-832 (1993).
26. K. Chiba, A. Saitoh, E. Koyama, M. Tani, M. Hayashi, and T. Ishizaki: The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br. J. Clin. Pharmacol. 37, 237-242 (1994).
27. E. Skjelbo and K. Brosen: Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34, 256-261 (1992).
28. P. M. Colangelo, R. A. Blouin, J. E. Steinmetz, P. J. McNamara, A. N. DeMaria, and P. J. Wedlund: Age and propranolol stereoselective disposition in humans. Clin. Pharmacol. Ther. 51, 489-494 (1992).
29. E. Chan, A. J. McLachlan, M. Pegg, A. D. MacKay, R. B. Cole, and M. Rowland: Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br. J. Clin. Pharmacol. 37, 563-569 (1994).
30. A. Breckenridge, M. Orme, H. Wesseling, R. J. Lewis, and R. Gibbons: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. 15, 424-430 (1974).
31. K. L. Kunze, A. C. Eddy, M. Gibaldi, and W. F. Trager: Metabolic enantiomeric interaction: The inhibition of human (S)-warfann-7-hydroxylase by (R)-warfarin. Chirality 3, 24-29 (1991).
32. C. G. Regardh: Pharmacokinetic aspects of some §-adrenoceptor blocking drugs. Acta Med. Scand. 665, 49-60 (1982).
33. T. Walle, U. K. Walle, and L. S. Olanoff: Quantitative account of propranolol metabolism in urine of normal man. Drug Metab. Dispos. 13, 204-209 (1985).
34. T. Walle, U. K. Walle, L. S. Olanoff, and E. C. Conradi: Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br. J. Clin. Pharmacol. 22, 317-323 (1986).
35. E. I. L. Ashforth, D. J. Carlile, R. Chenery, and J. B. Houston: Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J. Pharmacol. Exp. Ther. 274, 761-766 (1995).
36. R. A. Nand, H. Ghabrial, R. A. Smallwood, and D. J. Morgan: (S)-4′-Hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes. Xenobiotica 26, 1249-1261 (1996).
37. T. A. Moreland and D. S. Hewick: Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochem. Pharmacol. 24, 1953-1957 (1975).